In a retrospective study, researchers assessed the incidence of mild cognitive impairment and Alzheimer disease in patients with MS.

In an interim analysis of ENLIGHTEN, researchers described changes in cognitive function over 1 year in patients with MS.

Presenting at ACTRIMS 2025, researchers reported 4-year health-related quality of life and cognitive function data from patients with relapsing multiple sclerosis from the CLARIFY-MS Extension study.

Presenting at ACTRIMS 2025, researchers assessed the timing of meningococcal vaccination in patients from the CHAMPION-NMOSD trial transitioning from rituximab to ravulizumab.

Presenting at ACTRIMS 2025, researchers reported on the safety and clinical efficacy over 24 months of patients with relapsing multiple sclerosis switching to cladribine from natalizumab.

Presenting at ACTRIMS 2025, researchers determined whether telomere length as a biological aging marker varied among patients with pediatric-onset MS compared with age-similar healthy control individuals.

Presenting at ACTRIMS 2025, researchers analyzed disease activity via MRI and blood biomarkers in Black and Hispanic patients with multiple sclerosis after 96 weeks of ocrelizumab treatment during the CHIMES trial.

Presenting at ACTRIMS 2025, researchers described the association of ocrelizumab concentration with safety and efficacy outcomes in patients with relapsing multiple sclerosis treated with ocrelizumab for up to 10 years.

In a post hoc analysis, researchers assessed the maintenance of the efficacy and safety of transitioning from IV anti-CD20 therapy to ofatumumab by race/ethnicity subgroup in patients with relapsing multiple sclerosis.

Researchers sought to provide data on the safety and tolerability of 30-minute, 450 mg infusions at week 24 in patients with relapsing multiple sclerosis who are a part of the ongoing ENHANCE study.